OncoMatch/Clinical Trials/NCT07286149
A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F)
Is NCT07286149 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments for lung neoplasm malignant.
Treatment: MK-1084 · Patritumab deruxtecan · Sacituzumab tirumotecan · Cetuximab · Rescue Medications — Researchers want to learn if MK-1084, the study medicine, can treat advanced or metastatic non-squamous NSCLC. MK-1084 is a targeted therapy, which is a treatment that works to control how specific types of cancer cells grow and spread. The goals of this study are to learn: * About the safety of MK-1084 and if people tolerate it when taken with other treatments * How many people have the cancer respond (get smaller or go away) to the treatments
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: KRAS g12c mutation
Disease stage
Metastatic disease required
advanced or metastatic non-squamous non-small cell lung cancer (NSCLC)
Prior therapy
Must have received: anti-PD-1 therapy
documented disease progression after receiving 1-2 prior lines of programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) therapy
Must have received: anti-PD-L1 therapy
documented disease progression after receiving 1-2 prior lines of programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) therapy
Must have received: platinum-based chemotherapy
documented disease progression after receiving 1-2 prior lines of ... platinum-based chemotherapy
Cannot have received: KRAS inhibitor
Has received previous treatment with an agent targeting KRAS
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Clermont Oncology Center ( Site 0041) · Clermont, Florida
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify